InSpira Medical Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2005
NCT00245297
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Alternative names

Inspira Medical AB | Recoly C/o InSpira Medical AB, Nasbyv 38, 13553 Tyreso Sweden

Active Ingredients

Drugs in Phase 2 Trials (3)

antihemophilic factor viii human (Hemofil M) (1 trial)

sodium chloride (1 trial)

teplizumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemophilia A (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hepatitis, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3